EVALUATION OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN METASTATIC BREAST CANCER: SYSTEMATIC REVIEW AND TRIAL LEVEL META-ANALYSIS

被引：0
|
作者：
Adunlin, G. [1 ]
Dranitsaris, G. [2 ]
机构：
[1] Virginia Commonwealth Univ, Richmond, VA USA
[2] Augmentium Pharma Consulting Inc, Toronto, ON, Canada
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1536
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN203
引用
收藏
页码：A170 / A170
页数：1
相关论文
共 50 条
  • [31] Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
    Paoletti, Xavier
    Lewsley, Liz-Anne
    Daniele, Gennaro
    Cook, Adrian
    Yanaihara, Nozomu
    Tinker, Anna
    Kristensen, Gunnar
    Ottevanger, Petronella B.
    Aravantinos, Gerasimos
    Miller, Austin
    Boere, Ingrid A.
    Fruscio, Robert
    Reyners, Anna K. L.
    Pujade-Lauraine, Eric
    Harkin, Andrea
    Pignata, Sandro
    Kagimura, Tatsuo
    Welch, Stephen
    Paul, James
    Karamouza, Eleni
    Glasspool, Rosalind M.
    JAMA NETWORK OPEN, 2020, 3 (01)
  • [32] Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review
    Lisa Belin
    Aidan Tan
    Yann De Rycke
    Agnès Dechartres
    British Journal of Cancer, 2020, 122 : 1707 - 1714
  • [33] Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis
    George Adunlin
    John W. W. Cyrus
    George Dranitsaris
    Breast Cancer Research and Treatment, 2015, 154 : 591 - 608
  • [34] Correlation between progression-free survival and overall survival in metastatic breast cancer patients receiving anthracyclines, taxanes, or targeted therapies: a trial-level meta-analysis
    Adunlin, George
    Cyrus, John W. W.
    Dranitsaris, George
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (03) : 591 - 608
  • [35] Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.
    Halabi, Susan
    Roy, Akash
    Yang, Qian
    Xie, Wanling
    Kelly, William Kevin
    Sweeney, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [36] Evaluation of progression-free survival as a surrogate end point in primary CNS lymphoma: a systematic review and meta-analysis
    Zhan, Jing
    Yang, Shijie
    Zhang, Wei
    Zhou, Daobin
    Zhao, Danqing
    Zhang, Yan
    Wang, Wei
    Wei, Chong
    FUTURE ONCOLOGY, 2023, 19 (31) : 2123 - 2133
  • [37] Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors
    Chowdhury, Simon
    Mainwaring, Paul
    Zhang, Liangcai
    Mundle, Suneel
    Pollozi, Eneida
    Gray, Alexander
    Wildgust, Mark
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [38] Progression-free survival as a surrogate for overall survival in advanced cancer.
    Gillies, Eric
    Holdai, Veera
    Cowall, David Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] IN ADVANCED/METASTATIC BREAST CANCER, IS PROGRESSION-FREE SURVIVAL A SURROGATE OUTCOME?
    Franca, A. C.
    Schroeder, L.
    Padilla, M.
    Meirelles, I
    Silva, A. S.
    Magliano, C.
    Santos, M.
    VALUE IN HEALTH, 2020, 23 : S477 - S478
  • [40] A trial-level correlation analysis of progression-free survival as a surrogate for overall survival in the immunotherapy era.
    Yekeduz, Emre
    Koksoy, Elif Berna
    Akbulut, Hakan
    Utkan, Gungor
    Urun, Yuksel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345